ERBB2 and breast carcinoma: In particular, it has been consistently demonstrated the phenomenon of both HR and HER2 status discordance between primary and recurrent breast cancer15–17, and biopsy of sites of locoregional relapse/distant metastasis is currently endorsed by international breast cancer guidelines8,18,19.